title: [Characteristics of therapy of acute myocardial infarction in diabetes].
abstract: Therapy of acute myocardial infarction (STEMI and NSTEMI) in diabetics does not principally differ from that of non-diabetic patients. Due to the higher mortality in diabetics reperfusion measures, such as direct percutaneous coronary intervention (PCI), should be rapidly performed. An intensive drug treatment with thrombocyte aggregation inhibitors, angiotensin-converting enzyme (ACE) inhibitors and beta-receptor blocking agents must be carried out according to the current guidelines. An important factor is the high risk of renal failure due to the contrast dye administered during PCI in the presence of pre-existing diabetic kidney damage which should be limited to 100 ml if possible. Direct PCI should be limited to the infarcted vessel. After stabilization a comprehensive strategy to cure coronary artery disease, whether with PCI or coronary artery bypass graft (CABG) should be finalized. If severe coronary 3-vessel disease is present, CABG should be favored in diabetic patients. After surviving an acute myocardial infarction differentiated metabolic monitoring is mandatory.
authors.affiliation: Klinik für Kardiologie, Herz- und Diabeteszentrum Mecklenburg-Vorpommern, Greifswalder Str. 11, 17495, Karlsburg, Deutschland. wmotz@drguth.de
authors.forename: W
authors.initials: W
authors.lastname: Motz
authors.forename: W
authors.initials: W
authors.lastname: Kerner
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D001798:Blood Proteins / Q000627:therapeutic use*; D001026:Coronary Artery Bypass / Q000379:methods*; D048909:Diabetes Complications / Q000175:diagnosis / Q000628:therapy*; D006801:Humans; D009203:Myocardial Infarction / Q000150:complications* / Q000175:diagnosis / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D001798:Blood Proteins; C024875:platelet adhesion inhibitor